PROCEPT BioRobotics reported robust third quarter 2025 results, achieving $83.3 million in total revenue, a 43% year-over-year increase, driven by strong capital system sales. The company remains focused on enhancing procedure utilization and expanding market awareness for its innovative Aquablation therapy.

• Total revenue reached $83.3 million, with U.S. sales contributing $73.9 million, showcasing solid growth amidst market scrutiny.
• 58 U.S. capital systems shipped in the quarter, indicating a stable pricing environment despite tightening capital budgets in large hospital systems.
• Organizational changes aimed at improving commercial execution, including expedited new account launches and a sharpened focus on international markets.
• Potential expansion into prostate cancer treatment, supported by the ongoing WATER IV clinical trial, highlights the long-term growth opportunities beyond BPH.
• Commitment to enhancing patient awareness and accelerating therapy adoption, leveraging new talent within leadership.